ERBB2 and breast carcinoma: Yet, among these ER(-) tumors, several teams have identified the molecular apocrine breast cancer (MA) subtype, characterized by AR expression and AR pathway activation on genome-wide expression analyses, paradoxical expression of genes known to be ER targets or expressed in ER(+) tumors and HER2 overexpression in around 50% of cases [3][4].